Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 23, 2025
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Journal: Cancer immunology research
Published: June 05, 2024
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: February 24, 2021
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Journal: Journal of medical case reports
Published: October 26, 2020
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Journal: Nature communications
Published: October 16, 2020
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: May 03, 2019
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.
Journal: Cancers
Published: June 09, 2017
Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival.
Journal: Molecular cancer therapeutics
Published: May 21, 2017
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.
Journal: Oncogene
Published: June 28, 2016
Last Updated: 09/26/2026